Compare SHAK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | GH |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 13.2B |
| IPO Year | 2015 | 2018 |
| Metric | SHAK | GH |
|---|---|---|
| Price | $90.44 | $111.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 21 |
| Target Price | ★ $117.30 | $99.48 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 425.42 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $1,373,459,000.00 | $902,569,000.00 |
| Revenue This Year | $18.39 | $35.00 |
| Revenue Next Year | $13.49 | $26.80 |
| P/E Ratio | $87.90 | ★ N/A |
| Revenue Growth | 13.49 | ★ 30.38 |
| 52 Week Low | $72.93 | $33.75 |
| 52 Week High | $144.65 | $112.44 |
| Indicator | SHAK | GH |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 68.33 |
| Support Level | $79.37 | $97.31 |
| Resistance Level | $85.56 | $104.75 |
| Average True Range (ATR) | 2.75 | 3.68 |
| MACD | 1.00 | 0.63 |
| Stochastic Oscillator | 81.44 | 86.53 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.